Refine by
Patient Management Articles & Analysis
270 news found
Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and ...
Performed by neurosurgeon Mark Luciano MD, PhD at The Johns Hopkins Hospital in Baltimore, Maryland, the patient previously required multiple brain surgeries to manage their “Idiopathic Intracranial Hypertension (IIH),” also referred to as “pseudotumor cerebri” because symptoms mimic those of a brain tumor. ...
The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. The addition of both assays further complements Tempus’ comprehensive testing ...
ByTempus
The iGEM (International Genetically Engineered Machine) Competition is an annual event in synthetic biology. Teams participating in iGEM typically spend several months conducting research, designing their projects, and building their biological systems. These projects can range from addressing real-world problems in areas such as healthcare, environmental sustainability, and manufacturing, to ...
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. ...
Proprietary data and software from both platforms will be used to create novel AI-based applications to improve the entire surgical continuum, including medical billing, patient pathway management, and revenue assurance. The collaboration will leverage a secure infrastructure that is compliant with data privacy, information security, and regulatory concerns ...
Treatment is often a tube (shunt) inserted surgically into a ventricle of the brain to drain excess fluid, but over time the device can often become dislodged or clogged which then requires more procedures and hospitalizations. Many patients require multiple brain surgeries to manage their hydrocephalus and their shunt. ...
In the clinical setting, rapid and accurate diagnosis is paramount to effective patient management. The Viral Metagenomic Sequencing service enhances clinical diagnostics by detecting coinfections, guiding treatment decisions, and improving disease surveillance. ...
Vitalograph has joined forces with MedM Inc. to further enhance patient respiratory monitoring experience with digital health capabilities. ...
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition of these hospitals contributes to the significant ...
Universal volume-directed interventions (i.e. diuretics) in HF patients with high pressures might not be appropriate and should be discouraged.” “Clinicians often rely on pressure monitoring alone to guide HF management by utilizing pressure measures as surrogates of volume status. This study confirms the significant body of evidence that pressure ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
The XARENO study results provide important evidence that can help physicians in the management of patients with atrial fibrillation and chronic kidney disease and help reduce patients’ risk of progressing to kidney failure,” said Reinhold Kreutz, Professor of Clinical Pharmacology, Charité - Universitätsmedizin Berlin, ...
ByBayer AG
Laurent Mesnard, Co-Director of the French National center for Thrombotic MicroAngiopathies (CNR-MAT), aimed at improving the diagnosis and management of patients suspected of suffering from thrombotic microangiopathies and atypical Hemolytic syndrome (aHUS). ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon ...
By eliminating the need for additional immunohistochemistry, 4D Path’s cloud-based platform accelerates complete, actionable and objective insight leading to expedited and democratized precision medicine for optimized patient care and clinical trials. 4D Path’s cloud-based, quantitative approach provides clinical solutions in both companion diagnostics and ...
In the program, APA ACO took on the risk for all of Medicare Part A and Part B for contracted and participating providers, meaning that APA ACO worked hand-in-hand with its providers to manage their patient population. For 2021, APA ACO's aggregate benchmark expenditure was $437.2 million, with actual expenditures amounting to $381.1 million, resulting in gross ...
“With limited access to novel agents in these markets and with large populations, a high unmet medical need exists in management of both patients with MM and DLBCL. When approved, XPOVIO® will offer an important novel treatment option in the care of patients with these life threatening diseases in Macau,China, Malaysia and ...
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. ...